{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T07:36:56Z","timestamp":1761896216281},"reference-count":43,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2016,3,1]],"date-time":"2016-03-01T00:00:00Z","timestamp":1456790400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["diabetesresearchclinicalpractice.com","clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Diabetes Research and Clinical Practice"],"published-print":{"date-parts":[[2016,3]]},"DOI":"10.1016\/j.diabres.2015.12.021","type":"journal-article","created":{"date-parts":[[2016,1,18]],"date-time":"2016-01-18T13:00:23Z","timestamp":1453122023000},"page":"143-151","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"special_numbering":"C","title":["Strategies for glucose control in a study population with diabetes, renal disease and anemia (Treat study)"],"prefix":"10.1016","volume":"113","author":[{"given":"Larry A.","family":"Weinrauch","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John A.","family":"D\u2019Elia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Finn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eldrin F.","family":"Lewis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akshay S.","family":"Desai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brian L.","family":"Claggett","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark E.","family":"Cooper","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Janet B.","family":"McGill","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.diabres.2015.12.021_bib0220","doi-asserted-by":"crossref","first-page":"2342","DOI":"10.1111\/jgs.12035","article-title":"Consensus development conference on diabetes and older adults. Diabetes in older adults: a consensus report","volume":"60","author":"Kirkman","year":"2012","journal-title":"J Am Geriatr Soc"},{"key":"10.1016\/j.diabres.2015.12.021_bib0225","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1056\/NEJM199311113292004","article-title":"The effect of angiotensin converting enzyme inhibition on diabetic nephropathy. The Collaborative Study Group","volume":"329","author":"Lewis","year":"1993","journal-title":"N Engl J Med"},{"key":"10.1016\/j.diabres.2015.12.021_bib0230","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1056\/NEJMoa011161","article-title":"Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy","volume":"345","author":"Brenner","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.diabres.2015.12.021_bib0235","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1056\/NEJMoa041365","article-title":"Relation between renal dysfunction and cardiovascular outcomes after myocardial infarction","volume":"351","author":"Anavekar","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.diabres.2015.12.021_bib0240","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1056\/NEJMoa0801317","article-title":"Telmisartan, ramipril, or both in patients at high risk for vascular events","volume":"358","author":"Yusuf","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.diabres.2015.12.021_bib0245","doi-asserted-by":"crossref","first-page":"2204","DOI":"10.1056\/NEJMoa1208799","article-title":"Cardiorenal end points in a trial of aliskiren for type 2 diabetes","volume":"367","author":"Parving","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.diabres.2015.12.021_bib0250","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1001\/jama.2013.1954","article-title":"Effect of aliskiren on postdischarge mortality and heart failure readmissions among patients hospitalized for heart failure: the ASTRONAUT randomized trial","volume":"309","author":"Gheorghiade","year":"2013","journal-title":"JAMA"},{"key":"10.1016\/j.diabres.2015.12.021_bib0255","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1016\/S0735-1097(03)00159-1","article-title":"Fluid retention after initiation of thiazolidinedione therapy in diabetic patients with established chronic heart failure","volume":"41","author":"Tang","year":"2003","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.diabres.2015.12.021_bib0260","doi-asserted-by":"crossref","first-page":"256","DOI":"10.2337\/diacare.27.1.256","article-title":"Thiazolidinedione use, fluid retention, and congestive heart failure: a consensus statement from the American Heart Association and American Diabetes Association","volume":"27","author":"Nesto","year":"2004","journal-title":"Diabetes Care"},{"key":"10.1016\/j.diabres.2015.12.021_bib0265","doi-asserted-by":"crossref","first-page":"536","DOI":"10.4158\/EP13176.CS","article-title":"American Association of Clinical Endocrinologists comprehensive diabetes management algorithm 2013 consensus statement\u2014executive summary","volume":"19","author":"Garber","year":"2013","journal-title":"Endocr Pract"},{"key":"10.1016\/j.diabres.2015.12.021_bib0270","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.2337\/dc12-0413","article-title":"Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)","volume":"35","author":"Inzucchi","year":"2012","journal-title":"Diabetes Care"},{"key":"10.1016\/j.diabres.2015.12.021_bib0275","doi-asserted-by":"crossref","first-page":"2567","DOI":"10.1161\/CIRCULATIONAHA.113.006634","article-title":"Glycemic management in patients with coronary artery disease and prediabetes or type 2 diabetes mellitus","volume":"129","author":"Goldfine","year":"2014","journal-title":"Circulation"},{"key":"10.1016\/j.diabres.2015.12.021_bib0280","doi-asserted-by":"crossref","first-page":"2705","DOI":"10.1161\/CIRCULATIONAHA.113.008221","article-title":"Cardiovascular safety in the development of new drugs for diabetes mellitus","volume":"129","author":"Menon","year":"2014","journal-title":"Circulation"},{"key":"10.1016\/j.diabres.2015.12.021_bib0285","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.2337\/dc10-2377","article-title":"Glycemic control, complications, and death in older diabetic patients: the diabetes and aging study","volume":"34","author":"Huang","year":"2011","journal-title":"Diabetes Care"},{"key":"10.1016\/j.diabres.2015.12.021_bib0290","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1016\/j.ahj.2004.09.047","article-title":"Rationale- Trial to reduce cardiovascular events with aranesp therapy (TREAT): evolving the management of cardiovascular risk in patients with chronic kidney disease","volume":"149","author":"Mix","year":"2005","journal-title":"Am Heart J"},{"key":"10.1016\/j.diabres.2015.12.021_bib0295","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1053\/j.ajkd.2009.04.008","article-title":"Baseline characteristics in the trial to reduce cardiovascular events with aranesp therapy (TREAT)","volume":"54","author":"Pfeffer","year":"2009","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.diabres.2015.12.021_bib0300","doi-asserted-by":"crossref","first-page":"2019","DOI":"10.1056\/NEJMoa0907845","article-title":"A trial of darbopoietin alfa in type 2 diabetes and chronic renal disease","volume":"361","author":"Pfeffer","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.diabres.2015.12.021_bib0305","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1053\/j.ajkd.2012.07.005","article-title":"KDOQI clinical practice guideline for diabetes and CKD: 2012 update","volume":"60","author":"National Kidney Foundation","year":"2012","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.diabres.2015.12.021_bib0310","series-title":"National diabetes statistics report","author":"National Center for Chronic Disease Prevention and Health Promotion, Division of Diabetes Translation","year":"2014"},{"key":"10.1016\/j.diabres.2015.12.021_bib0315","doi-asserted-by":"crossref","first-page":"2503","DOI":"10.1056\/NEJMoa0805796","article-title":"A randomized trial of therapies for type 2 diabetes and coronary artery disease","volume":"360","author":"Frye","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.diabres.2015.12.021_bib0320","doi-asserted-by":"crossref","first-page":"3208","DOI":"10.2337\/dc13-0012","article-title":"Impact of glycemic control strategies on the progression of diabetic peripheral neuropathy in the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) Cohort","volume":"36","author":"Pop-Busui","year":"2013","journal-title":"Diabetes Care"},{"key":"10.1016\/j.diabres.2015.12.021_bib0325","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1007\/s12325-013-0039-y","article-title":"Complementing insulin therapy to achieve glycemic control","volume":"30","author":"Barnett","year":"2013","journal-title":"Adv Ther"},{"key":"10.1016\/j.diabres.2015.12.021_bib0330","doi-asserted-by":"crossref","first-page":"602","DOI":"10.7326\/0003-4819-154-9-201105030-00336","article-title":"Comparative effectiveness and safety of medications for type 2 diabetes: an update including new drugs and 2-drug combinations","volume":"154","author":"Bennett","year":"2011","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.diabres.2015.12.021_bib0335","doi-asserted-by":"crossref","first-page":"b4731","DOI":"10.1136\/bmj.b4731","article-title":"Risk of cardiovascular disease and all cause mortality among patients with type 2 diabetes prescribed oral antidiabetes drugs: retrospective cohort study using UK general practice research database","volume":"339","author":"Tzoulaki","year":"2009","journal-title":"BMJ"},{"issue":"22","key":"10.1016\/j.diabres.2015.12.021_bib0340","doi-asserted-by":"crossref","first-page":"2315","DOI":"10.1001\/jama.2014.5951","article-title":"Insulin therapy for type 2 diabetes mellitus","volume":"3111","author":"Wallia","year":"2014","journal-title":"JAMA"},{"issue":"2","key":"10.1016\/j.diabres.2015.12.021_bib0345","first-page":"259","article-title":"Diabetes overtreatment in elderly individuals: risk business in need of better management","volume":"174","author":"Andrews","year":"2014","journal-title":"JAMA"},{"key":"10.1016\/j.diabres.2015.12.021_bib0350","doi-asserted-by":"crossref","first-page":"1660","DOI":"10.2337\/dc13-2036","article-title":"Improved survival and renal prognosis of patients with type 2 diabetes and nephropathy with improved control of risk factors","volume":"37","author":"Andresdottir","year":"2014","journal-title":"Diabetes Care"},{"key":"10.1016\/j.diabres.2015.12.021_bib0355","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.2337\/dc13-2573","article-title":"Insulin sensitivity and albuminuria: the RISC study","volume":"37","author":"Pilz","year":"2014","journal-title":"Diabetes Care"},{"key":"10.1016\/j.diabres.2015.12.021_bib0360","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.2337\/dc13-2334","article-title":"Outcomes of combined cardiovascular risk factor management strategies in type 2 diabetes: the ACCORD randomized trial","volume":"37","author":"Margolis","year":"2014","journal-title":"Diabetes Care"},{"key":"10.1016\/j.diabres.2015.12.021_bib0365","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1111\/jgs.12381","article-title":"Age, renal dysfunction, cardiovascular disease, and antihyperglycemic treatment in type 2 diabetes mellitus: findings from the Renal Insufficiency and Cardiovascular Events Italian Multicenter Study","volume":"61","author":"Solini","year":"2013","journal-title":"Am Geriatr Soc"},{"key":"10.1016\/j.diabres.2015.12.021_bib0370","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/S0140-6736(10)60576-4","article-title":"Effect of intensive treatment of hyperglycemia on microvascular outcomes in type 2 diabetes: an analysis of the ACCORD randomized trial","volume":"376","author":"Ismail-Beigi","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.diabres.2015.12.021_bib0375","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1681\/ASN.2008121270","article-title":"Albuminuria and kidney function independently predict cardiovascular and renal outcomes in diabetes","volume":"20","author":"Ninomiya","year":"2009","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.diabres.2015.12.021_bib0380","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1016\/S0140-6736(98)07019-6","article-title":"Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)","volume":"352","author":"UK Prospective Diabetes Study Group","year":"1998","journal-title":"Lancet"},{"key":"10.1016\/j.diabres.2015.12.021_bib0385","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1016\/S0140-6736(98)07037-8","article-title":"Effect of intensive blood\u2013glucose control with metformin on complications in overweight patient with type 2 diabetes (UKPDS 34)","volume":"352","author":"UK Prospective Diabetes Study Group","year":"1998","journal-title":"Lancet"},{"key":"10.1016\/j.diabres.2015.12.021_bib0390","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.mcna.2012.11.001","article-title":"Diabetes management in the kidney patient","volume":"97","author":"Garg","year":"2013","journal-title":"Med Clin North Am"},{"key":"10.1016\/j.diabres.2015.12.021_bib0395","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1056\/NEJMcibr1409796","article-title":"The target of metformin in type 2 diabetes","volume":"371","author":"Ferrannini","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.diabres.2015.12.021_bib0400","doi-asserted-by":"crossref","first-page":"2288","DOI":"10.1001\/jama.2014.4312","article-title":"Association between intensification of metformin treatment with insulin vs. sulfonylureas and cardiovascular events and all cause mortality among patients with diabetes","volume":"311","author":"Roumie","year":"2014","journal-title":"JAMA"},{"issue":"1","key":"10.1016\/j.diabres.2015.12.021_bib0405","first-page":"CD002967","article-title":"Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus","author":"Salpeter","year":"2006","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.diabres.2015.12.021_bib0410","doi-asserted-by":"crossref","first-page":"2454","DOI":"10.1007\/s00125-005-0026-1","article-title":"Contraindications can damage your health\u2014is metformin a case in point?","volume":"48","author":"Holstein","year":"2005","journal-title":"Diabetologia"},{"key":"10.1016\/j.diabres.2015.12.021_bib0415","doi-asserted-by":"crossref","first-page":"2668","DOI":"10.1001\/jama.2014.15298","article-title":"Metformin in patients with type 2 diabetes and kidney disease: a systematic review","volume":"312","author":"Inzucchi","year":"2014","journal-title":"JAMA"},{"key":"10.1016\/j.diabres.2015.12.021_bib0420","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.2337\/dc10-2361","article-title":"Use of metformin in the setting of mild-to-moderate renal insufficiency","volume":"34","author":"Lipska","year":"2011","journal-title":"Diabetes Care"},{"key":"10.1016\/j.diabres.2015.12.021_bib0425","doi-asserted-by":"crossref","first-page":"2059","DOI":"10.2337\/dc15-0542","article-title":"For the CDC CKD Surveillance Team","volume":"38","author":"Tuot","year":"2015","journal-title":"Diabetes Care"},{"key":"10.1016\/j.diabres.2015.12.021_bib0430","doi-asserted-by":"crossref","first-page":"3403","DOI":"10.1681\/ASN.2005030226","volume":"16","author":"Vlagopoulos","year":"2005","journal-title":"J Am Soc Nephrol"}],"container-title":["Diabetes Research and Clinical Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168822716000292?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168822716000292?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,16]],"date-time":"2018-09-16T00:00:14Z","timestamp":1537056014000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168822716000292"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,3]]},"references-count":43,"alternative-id":["S0168822716000292"],"URL":"https:\/\/doi.org\/10.1016\/j.diabres.2015.12.021","relation":{},"ISSN":["0168-8227"],"issn-type":[{"value":"0168-8227","type":"print"}],"subject":[],"published":{"date-parts":[[2016,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Strategies for glucose control in a study population with diabetes, renal disease and anemia (Treat study)","name":"articletitle","label":"Article Title"},{"value":"Diabetes Research and Clinical Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.diabres.2015.12.021","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2016 Elsevier Ireland Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}